TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Mayne Pharma Group ( (AU:MYX) ) just unveiled an update.
Mayne Pharma Group Limited has issued a notice of intention to terminate the Scheme Implementation Deed with Cosette Pharmaceuticals due to material breaches by Cosette. These breaches include failing to meet obligations related to FIRB approval and debt financing, which could impact the proposed acquisition. Mayne Pharma reserves the right to terminate the agreement if the breaches are not resolved within five business days, potentially affecting its strategic plans and stakeholder interests.
The most recent analyst rating on (AU:MYX) stock is a Sell with a A$3.50 price target. To see the full list of analyst forecasts on Mayne Pharma Group stock, see the AU:MYX Stock Forecast page.
More about Mayne Pharma Group
Mayne Pharma is an ASX-listed specialty pharmaceutical company that focuses on commercializing novel pharmaceuticals to offer patients better, safer, and more accessible medicines. It is a leader in dermatology and women’s health in the United States and provides contract development and manufacturing services globally. With a 40-year history of innovation, Mayne Pharma has successfully developed and commercialized new oral drug delivery systems.
Average Trading Volume: 562,979
Technical Sentiment Signal: Sell
Current Market Cap: A$296.5M
For detailed information about MYX stock, go to TipRanks’ Stock Analysis page.